Two investigators (HW and TG) independently performed the data extraction from each publication using a standardized form: publication data, baseline characteristics of the study population (sample size, sex, age, body mass index (BMI), body weight, abdominal circumference, waist-to-hip ratio, visceral adipose tissue (measured by computed tomography, magnetic resonance imaging, or dual-emission X-ray absorptiometry)), duration of follow-up, weight change during treatment and after treatment discontinuation, description of the weight management group and control group
Health and well-being coaching adjuvant to GLP-1 induced weight loss
GLP-1 receptor agonists are not new drugs
TSH, thyroid stimulating hormone
National Institute of Diabetes and Digestive and Kidney Diseases: Prescription Medications to Treat Overweight and Obesity Peterson-KFF Health System Tracker: Perspectives From Employers on the Costs and Issues Associated With Covering GLP-1 Agonists for Weight Loss Costly GLP-1 Drugs are Rarely Covered for Weight Loss by Marketplace Plans
